Skip to main content
editorial
. 2018 Sep 24;7(2):195–206. doi: 10.1007/s40120-018-0111-2

Fig. 2.

Fig. 2

Responder rates in patients included in the ESL phase III adjunctive therapy trials who were not receiving CBZ or who were receiving CBZ. Response was defined as at least 50% seizure frequency reduction from baseline [30]. CBZ carbamazepine, ESL eslicarbazepine acetate